Module 2

Part 1: Diagnosis of lymphoma & diagnostic tests explained
Dr Colm Keane – Consultant Haematologist, Princess Alexandra Hospital & Mater Hospital, Brisbane

Dr Keane splits his time evenly between treating lymphoma patients at the Princess Alexandra Hospital and searching for better treatments in his laboratory next door at the TRI, where he is an NHMRC Early Career Fellow with Mater Research (University of Queensland). Dr Keane is particularly interested in harnessing the immune system to help improve patient outcomes, with a particular interest in rare lymphomas. Dr Keane has a Masters in Haematopathology from the University of York and an MBA from Griffith University. He also completed his PhD in lymphoma research with Griffith University in 2015. While undertaking his PhD, he held a Research Fellowship at the QIMR Berghofer Medical Research Institute, before taking up a joint position with Mater Research and The University of Queensland.

Part 2: Staging of lymphoma: prognostic factors & scans explained
Dr Collin Chin, Haematology Fellow, Sir Charles Gairdner Hospital, Perth

Dr Collin Chin is a Haematology Fellow at Sir Charles Gairdner Hospital, in Perth. He graduated in Medicine from the University of Western Australia in 2011 and completed his specialist training at Sir Charles Gairdner Hospital, Perth followed by an Aggressive Lymphoma & Chimaeric Antigen Receptor (CAR) T-cell therapy fellowship at Peter MacCallum Cancer Centre in Melbourne, Victoria.

Collin has a specialist interest in the management of aggressive & indolent lymphoproliferative disorders, early phase clinical trials and immune effector cell (IEC) therapies including bispecific antibodies & CAR T-cell therapies. He has expertise in CAR T-cell therapy in high-risk and/or relapsed DLBCL & follicular lymphoma,having treated the first patients to receive CAR T-cells in Australia at the Peter MacCallum Cancer Centre. Collin has also co-authored the CAR T-cell referral pathway & toxicity management guidelines at the Peter MacCallum Cancer Centre.

After completing his fellowship at the MD Anderson Cancer Center, Collin’s plan is to return to Perth and establish an immune effector cell (IEC) therapy unit for the treatment of high risk, relapsed and/or refractory lymphoproliferative disorders in Western Australia.